C57BL/6JCya-Btnl9em1flox/Cya
Common Name:
Btnl9-flox
Product ID:
S-CKO-07946
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Btnl9-flox
Strain ID
CKOCMP-237754-Btnl9-B6J-VA
Gene Name
Product ID
S-CKO-07946
Gene Alias
B430208I01; Btn3; D330012D11Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
11
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Btnl9em1flox/Cya mice (Catalog S-CKO-07946) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000046522
NCBI RefSeq
NM_172793
Target Region
Exon 2~4
Size of Effective Region
~5.8 kb
Detailed Document
Overview of Gene Research
Btnl9, or butyrophilin-like protein 9, is a member of the immunoglobulin families. It has been implicated in immune-related and cancer-related pathways [1]. Functional enrichment analyses suggest its involvement in various biological processes relevant to disease mechanisms.
In multiple cancer types, studies have shown significant associations. In thyroid cancer (THCA), BTNL9 expression is down-regulated, related to tumor stages, immune cell infiltrations, and prognosis, with lower expression associated with a poorer progression-free interval (PFI) [1]. In breast cancer, its down-regulation is common, and ectopic expression inhibits cell proliferation, colony formation, and metastasis, while inducing apoptosis, acting via the P53/CDC25C and P53/GADD45 pathways [2]. In non-small-cell lung cancer, lncRNA CALML3-AS1 drives cancer progression by epigenetically repressing BTNL9 [3]. In uveal melanoma, high BTNL9 expression is associated with a favorable prognosis, and it can suppress invasion [4]. In lung adenocarcinoma, its down-regulation is linked to a poor overall survival probability, and it is positively correlated with immune-related scores and immune cell infiltration levels [5]. In pancreatic cancer, decreased BTNL9 expression is associated with a reduced survival rate [6]. In BRAF-mutated peritoneal metastasis from colorectal cancer, increased expression of BTNL9 is observed [7].
In idiopathic pulmonary fibrosis, BTNL9 is down-regulated, and it may have a protective effect by inhibiting extracellular matrix production and promoting wound repair [8]. In ALS, a negative correlation between BTNL9 and ALS risk was identified through Mendelian randomization analysis [9].
In conclusion, BTNL9 appears to play diverse roles in multiple diseases, especially in various cancers and potentially in neurodegenerative and fibrotic diseases. Its down-regulation is often associated with poor prognosis in cancer, and it is involved in regulating cell proliferation, metastasis, and immune-related processes. These findings from different disease-based studies contribute to understanding its biological functions and potential as a biomarker or therapeutic target.
References：
1. Zhang, Luyao, Yu, Shuang, Hong, Shubin, Li, Yanbing, Xiao, Haipeng. 2023. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer. In BMC medical genomics, 16, 234. doi:10.1186/s12920-023-01676-8. https://pubmed.ncbi.nlm.nih.gov/37798795/
2. Mo, Qingfan, Xu, Ke, Luo, Chenghao, Wang, Long, Ren, Guosheng. 2021. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. In Biochemical and biophysical research communications, 553, 17-24. doi:10.1016/j.bbrc.2021.03.022. https://pubmed.ncbi.nlm.nih.gov/33756341/
3. Zhang, Heng, Wang, Shao-Qiang, Zhu, Jie-Bo, Duan, Chao-Jun, Zhang, Chun-Fang. 2023. LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression. In Cancer gene therapy, 30, 1649-1662. doi:10.1038/s41417-023-00670-7. https://pubmed.ncbi.nlm.nih.gov/37884580/
4. Jiang, Zhongming, Liu, Fei. 2019. Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma. In Medical science monitor : international medical journal of experimental and clinical research, 25, 3190-3198. doi:10.12659/MSM.914074. https://pubmed.ncbi.nlm.nih.gov/31039142/
5. Ma, Weishuang, Liang, Jiaming, Mo, Junjian, Tian, Dongbo, Chen, Zisheng. 2021. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. In BMC cancer, 21, 1096. doi:10.1186/s12885-021-08790-9. https://pubmed.ncbi.nlm.nih.gov/34635082/
6. Khojasteh-Leylakoohi, Fatemeh, Mohit, Reza, Khalili-Tanha, Nima, Batra, Jyotsna, Avan, Amir. 2023. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. In Scientific reports, 13, 16678. doi:10.1038/s41598-023-42928-y. https://pubmed.ncbi.nlm.nih.gov/37794108/
7. Lund-Andersen, Christin, Torgunrud, Annette, Kanduri, Chakravarthi, Larsen, Stein G, Flatmark, Kjersti. 2024. Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. In Journal of translational medicine, 22, 646. doi:10.1186/s12967-024-05467-2. https://pubmed.ncbi.nlm.nih.gov/38982444/
8. Zheng, Peiyan, Sun, Shixue, Wang, Jingxian, Zhang, Xiaohua Douglas, Sun, Baoqing. 2022. Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis. In Cellular and molecular life sciences : CMLS, 79, 66. doi:10.1007/s00018-021-04094-0. https://pubmed.ncbi.nlm.nih.gov/35015148/
9. Lu, Chuan, Huang, Xiao-Xiao, Huang, Ming, Liu, Chaoning, Xu, Jianwen. 2025. Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses. In BMC neurology, 25, 82. doi:10.1186/s12883-025-04091-x. https://pubmed.ncbi.nlm.nih.gov/40033250/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen